Results 71 to 80 of about 1,121 (157)

Real‐world data of Brazilian adults with X‐linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts

Molecular Genetics & Genomic Medicine
Background Disease‐related variants in PHEX cause XLH by an increase of fibroblast growth factor 23 (FGF23) circulating levels, resulting in hypophosphatemia and 1,25(OH)2 vitamin D deficiency.
Maria Helena Vaisbich, Antônio César Paulillo deCillo, Bárbara Campolina C. Silva, Catarina Brasil DÁlva, Érico Higino deCarvalho, Juliana M. C. M. deAlmeida, Larissa L. M. Marques, Marcia Ribeiro, Mauro Borghi M. daSilva, Paula Frassinetti V. deMedeiros, Pedro Henrique Mendes   +10 more
doaj   +1 more source

Burosumab [PDF]

, 2020
openaire   +1 more source

Meta-analysis and systematic review: burosumab as a promising treatment for children with X-linked hypophosphatemia

Frontiers in Endocrinology
ObjectiveThe aim of this study was to evaluate the effectiveness of burosumab therapy in children with X-Linked Hypophosphatemia (XLH).Materials and methodsWe systematically reviewed literature from PubMed, Web of Science, The Cochrane Library, and ...
Kangning Wang, Runze Zhang, Ziyi Chen, Yi Bai, Qing He   +4 more
doaj   +1 more source

The importance of early diagnosis of X-linked hypophosphatemic rickets: a case report

Atti della Accademia Peloritana dei Pericolanti - Classe di Scienze Medico-Biologiche
X-linked hypophosphatemic rickets (XLH) is the commonest inherited form of rickets. XLH is caused by an impaired regulation of fibroblast growth factor 23 (FGF23) due to a PHEX gene mutation, leading to chronic renal phosphate excretion and impairment of
Francesca Franchina, Fabio Toscano, Giovanni Luppino, Giorgia Pepe, Tommaso Aversa, Domenico Corica   +5 more
doaj   +1 more source

Health-Related Quality of Life in Children with X-Linked Hypophosphatemia Treated with Burosumab: Real-World Data from a German-Swiss Study. [PDF]

Calcif Tissue Int
Böckmann I, Klein M, Mutze H, Rehberg M, Spartà G, Evers K, Schlingmann KP, Kemper MJ, Richter-Unruh A, Schmidt D, Hiort O, Grohmann-Held K, Schröder C, Derichs U, Freiberg C, Weitz M, Dunstheimer D, Schmid E, John-Kroegel U, Metzing O, Heger S, Jorch N, Staude H, Patzer L, Wühl E, Partsch CJ, Hübner A, Marx M, Land C, Albers N, Banzer J, Baus I, Wilkening F, Möller K, Wagner V, Krauch G, Gessner M, Goischke A, Leifheit-Nestler M, Zivicnjak M, Schnabel D, Haffner D, German Society for Pediatric Nephrology (GPN) and the German Society for Pediatric and Adolescent Endocrinology and Diabetology (DGPAED).   +42 more
europepmc   +1 more source

Burosumab as bridging therapy in autosomal dominant hypophosphatemic rickets with femoral fracture nonunion and iron deficiency. [PDF]

JBMR Plus
Rakusa M, Kocjan T.
europepmc   +1 more source

Continuation of burosumab during pregnancy in a patient with X-linked hypophosphatemia. [PDF]

JCEM Case Rep
Suzuki A, Moriyama Y, Mizuno H, Nishizawa H.   +3 more
europepmc   +1 more source

Impact of burosumab on kinetics of intact FGF23 values after the removal of a causative tumor in a patient with tumor-induced osteomalacia. [PDF]

JBMR Plus
Irie K, Sasaki K, Furukawa K, Jiajue R, Adachi N, Kimura S, Hoshino Y, Hidaka N, Kato H, Takeuchi M, Tanaka S, Nangaku M, Saito T, Makita N, Ito N.   +14 more
europepmc   +1 more source

Orthopaedic diagnostic pitfalls in fibroblast growth factor 23-mediated hypophosphatemic rickets/osteomalacia in fibrous dysplasia/McCune-Albright syndrome: Two burosumab-treated cases. [PDF]

Bone Rep
Nakagawa T, Imanishi J, Koda A, Matsuyama T, Sato K, Yamamoto A, Matsui K, Watanabe Y, Kawano H.   +8 more
europepmc   +1 more source

Recurrent Tumor-Induced Osteomalacia After Surgical Resection: A Case Report Demonstrating Successful Treatment With Burosumab. [PDF]

Cureus
Nicolau C, Vieira MB, Melo JD, Zhu C, Fonseca L, Calado J, Ferreira AC, Jorge C, Ferreira A.   +8 more
europepmc   +1 more source